S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma

[1] Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403

[2] Steliarova-Foucher E(2016)Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980–2012 Acta Oncol 55 40-45

[3] Lortet-Tieulent J(2013)Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients Eur J Cancer 49 98-105

[4] Rosso S(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413

[5] Coebergh JW(2008)Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 82-1703

[6] Comber H(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1825

[7] Forman D(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1553

[8] Bray F(2010)Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 1547-855

[9] Bjerregaard JK(2013)S-1 (Teysuno(R)): a review of its use in advanced gastric cancer in non-Asian populations Drugs 73 845-1204

[10] Mortensen MB(2012)Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study) Cancer Chemother Pharmacol 69 1197-1939

[1] Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403

[2] Steliarova-Foucher E(2016)Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980–2012 Acta Oncol 55 40-45

[3] Lortet-Tieulent J(2013)Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients Eur J Cancer 49 98-105

[4] Rosso S(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413

[5] Coebergh JW(2008)Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer BMC Cancer 8 82-1703

[6] Comber H(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1825

[7] Forman D(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1553

[8] Bray F(2010)Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 1547-855

[9] Bjerregaard JK(2013)S-1 (Teysuno(R)): a review of its use in advanced gastric cancer in non-Asian populations Drugs 73 845-1204

[10] Mortensen MB(2012)Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study) Cancer Chemother Pharmacol 69 1197-1939